Handelsavisen
prelaunch
Companies Healthcare 0286.HK
02
0286.HK HKEX Healthcare Facilities & Services

0286.Hk

HK$1,31
Open in Charts → Attach watcher ⌖
HKD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
251,8M HKD
P/E
EV / Rev
Div yield
Op margin
-19,9 %
ROE
-24,1 %
Net margin
-32,0 %
Debt / equity
1,15
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

The company operates in the healthcare sector, focusing on biotechnology and providing healthcare services and equipment.

Business. The company operates in the healthcare sector, focusing on biotechnology and providing healthcare services and equipment.

Classification92 %
SectorHealthcare
Business sectorHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
ActivityBiotechnology
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
-24,1 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 0286.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 0286.HK. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    The company operates in the healthcare sector, focusing on biotechnology and providing healthcare services and equipment.

    Classification92 %
    SectorHealthcare
    Business sectorHealthcare Services & Equipment
    IndustryHealthcare Facilities & Services
    ActivityBiotechnology
    AI synthesis
    GENERATED

    The company's capital structure is characterized by a debt-to-equity ratio of 1.15, indicating a moderate level of leverage. Its liquidity position is assessed as medium, with a current ratio of 1.16, suggesting the company has sufficient short-term assets to cover its short-term liabilities. The price-to-book ratio of 0.34 indicates that the company's market value is significantly below its book value, which may reflect market skepticism about its future earnings potential.

    Profitability metrics show a challenging financial position, with a negative return on equity of -24.05% and a negative return on assets of -9.05%. These figures indicate that the company is not generating returns for its shareholders or effectively utilizing its assets to generate profit. The operating margin is negative, with an operating loss of 110,306,000 HKD, and the net loss of 177,421,000 HKD further underscores the company's financial difficulties.

    The company's revenue is primarily concentrated in a single segment, with no disclosed geographic diversification. This lack of diversification increases the company's exposure to regional economic fluctuations and regulatory changes. The absence of detailed segment reporting limits the ability to assess the performance of different parts of the business.

    The company's growth trajectory is uncertain, with a net loss in the most recent fiscal year. The outlook for the current fiscal year does not provide specific numeric deltas, but the company's financial performance suggests a need for significant operational improvements to achieve profitability. The capital expenditure of -36,369,000 HKD indicates ongoing investment in the business, which may be aimed at driving future growth.

    Risk factors include a medium liquidity risk, as the company has negative net cash after subtracting total debt. The dilution risk is assessed as low, with no immediate pressure for additional share issuance. The company's financial structure and negative cash flow from operations pose a credit risk, which could affect its ability to secure financing on favorable terms.

    Recent events include the disclosure of a net loss and a negative operating income, which are reflected in the company's financial statements. There are no recent filings or transcripts that provide additional insights into the company's strategic direction or operational performance.

    Key takeaways
    • The company is currently unprofitable, with a net loss of 177,421,000 HKD and a negative return on equity of -24.05%.
    • The company's liquidity position is medium, with a current ratio of 1.16 and a debt-to-equity ratio of 1.15.
    • The company's revenue is concentrated in a single segment, increasing its exposure to regional economic and regulatory risks.
    • The company's capital expenditure of -36,369,000 HKD suggests ongoing investment, but the financial performance indicates a need for significant operational improvements.
    • The company's risk assessment highlights a medium liquidity risk and a low dilution risk, with no immediate pressure for additional share issuance.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    HK$1,31
    Market cap
    HK$253.7M
    Enterprise value
    HK$1.10B
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    13.3x
    P / B
    0.3x
    P / Tangible book
    0.3x
    Tangible book
    HK$737.7M
    Net cash
    -HK$847.4M
    Current ratio
    1.2
    Debt / equity
    1.1
    ROA
    -9.0%
    ROE
    -24.1%
    Cash conversion
    -47.0%
    CapEx / revenue
    -6.6%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin-19,9 %Bottom quartile
    Net Margin-32,0 %Bottom quartile
    ROE-24,1 %Bottom quartile
    Capex / Rev-6,6 %Above median
    D/E1,15Bottom quartile
    Cash Conv-0,47Bottom quartile

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Ev To Operating Cash Flow
      enterprise_value / operating_cash_flow
    • Return On Equity
      net_income / total_equity
    • Price To Book
      market_price / (adjusted_book_value / shares_outstanding_diluted)
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    • Market Cap
      market_price * shares_outstanding_diluted
    Source documents
    • 0286.HK Market data — financials · 2026-05-26
    • Aidigong Maternal & Child Health Ltd Market data — analyst estimates · 2026-05-26

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    0286.HKCanonical
    HKEX · HKD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage